Literature DB >> 29149574

Transscleral passive and iontophoretic transport: theory and analysis.

S Kevin Li1, Jinsong Hao2.   

Abstract

INTRODUCTION: The sclera is considered the 'static barrier,' a main barrier for transscleral drug delivery. The characterization of passive and iontophoretic transport across the sclera in vitro is the first step toward our ability to predict transscleral drug delivery. Although previous studies have investigated this topic, the quantitative structure permeation relationships (QSPR) for passive and iontophoretic transscleral transport are not available. AREAS COVERED: This review evaluated previous results of transscleral passive and iontophoretic transport in vitro and examined QSPR for transscleral permeation of small permeants and macromolecules. Passive permeation data in the literature were compared with respective to the animal species employed in the studies. Data variability was investigated. Electrotransport theory and the mechanisms of iontophoresis were reviewed and used to analyze the iontophoresis data. EXPERT OPINION: QSPR was examined for passive transscleral permeation, showing correlations between logarithm of permeability coefficient and logarithm of molecular weight. Potential causes of data variability were proposed. QSPR were established for electroosmosis using the molecular weight of neutral permeants and for iontophoresis enhancement using the molecular weight and charge of ionic permeants. However, QSPR for charged macromolecules were empirical; iontophoretic flux enhancement was significantly smaller than Nernst-Planck model prediction due to complicating factors.

Keywords:  Ocular delivery; diffusion; iontophoresis; quantitative structure permeation relationships (QSPR); sclera; transscleral

Mesh:

Year:  2017        PMID: 29149574     DOI: 10.1080/17425247.2018.1406918

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  8 in total

1.  Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules.

Authors:  Sarah Molokhia; Kongnara Papangkorn; Charlotte Butler; John W Higuchi; Balbir Brar; Balamurali Ambati; S Kevin Li; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2020-03-05       Impact factor: 2.671

2.  Management of Retinitis Pigmentosa via Platelet-Rich Plasma or Combination with Electromagnetic Stimulation: Retrospective Analysis of 1-Year Results.

Authors:  Umut Arslan; Emin Özmert
Journal:  Adv Ther       Date:  2020-04-18       Impact factor: 3.845

3.  Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results.

Authors:  Emin Özmert; Umut Arslan
Journal:  Stem Cell Res Ther       Date:  2020-01-13       Impact factor: 6.832

4.  Efficacy of Sub-Tenon Micro-Perfusion of Cyclophosphamide in Rabbits with Severe Ocular Inflammation.

Authors:  Libei Zhao; Manqiang Peng; Wenxiang Lin; Qian Tan; Muhammad Ahmad Khan; Ding Lin
Journal:  Drug Des Devel Ther       Date:  2020-08-20       Impact factor: 4.162

5.  Management of toxic optic neuropathy via a combination of Wharton's jelly-derived mesenchymal stem cells with electromagnetic stimulation.

Authors:  Emin Özmert; Umut Arslan
Journal:  Stem Cell Res Ther       Date:  2021-09-27       Impact factor: 6.832

6.  Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera.

Authors:  Steven A Giannos; Edward R Kraft; Zhen-Yang Zhao; Kevin H Merkley; Jiyang Cai
Journal:  Pharm Res       Date:  2018-03-29       Impact factor: 4.200

7.  Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results.

Authors:  Emin Özmert; Umut Arslan
Journal:  Stem Cell Res Ther       Date:  2020-08-12       Impact factor: 6.832

Review 8.  The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye.

Authors:  Lixiang Wang; Mikael Ben Zhou; Hui Zhang
Journal:  Ophthalmol Ther       Date:  2021-07-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.